KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deferred Tax Liability (2016 - 2023)

Inovio Pharmaceuticals (INO) has disclosed Non-Current Deferred Tax Liability for 14 consecutive years, with $32046.0 as the latest value for Q3 2023.

  • Quarterly Non-Current Deferred Tax Liability changed 0.0% to $32046.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $32046.0 through Sep 2023, changed 0.0% year-over-year, with the annual reading at $2.3 million for FY2022, 7223.85% up from the prior year.
  • Non-Current Deferred Tax Liability hit $32046.0 in Q3 2023 for Inovio Pharmaceuticals, roughly flat from $32046.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.3 million in Q4 2022 to a low of $24766.0 in Q1 2019.
  • Historically, Non-Current Deferred Tax Liability has averaged $152934.4 across 5 years, with a median of $32046.0 in 2019.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: changed 0.0% in 2019 and later soared 7223.85% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $32046.0 in 2019, then changed by 0.0% to $32046.0 in 2020, then changed by 0.0% to $32046.0 in 2021, then skyrocketed by 7223.85% to $2.3 million in 2022, then tumbled by 98.63% to $32046.0 in 2023.
  • Business Quant data shows Non-Current Deferred Tax Liability for INO at $32046.0 in Q3 2023, $32046.0 in Q2 2023, and $32046.0 in Q1 2023.